Amgen Inc. $AMGN Shares Sold by Savant Capital LLC

Savant Capital LLC lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 15.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 24,049 shares of the medical research company’s stock after selling 4,488 shares during the quarter. Savant Capital LLC’s holdings in Amgen were worth $7,872,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Moors & Cabot Inc. grew its stake in shares of Amgen by 2.4% during the fourth quarter. Moors & Cabot Inc. now owns 15,420 shares of the medical research company’s stock worth $5,047,000 after purchasing an additional 359 shares in the last quarter. Intech Investment Management LLC grew its stake in shares of Amgen by 9.4% during the fourth quarter. Intech Investment Management LLC now owns 52,904 shares of the medical research company’s stock worth $17,316,000 after purchasing an additional 4,540 shares in the last quarter. Investment Partners LTD. acquired a new position in Amgen in the fourth quarter valued at $207,000. Houlihan Financial Resource Group Ltd. boosted its stake in Amgen by 93.9% in the fourth quarter. Houlihan Financial Resource Group Ltd. now owns 3,291 shares of the medical research company’s stock valued at $1,102,000 after acquiring an additional 1,594 shares in the last quarter. Finally, CFS Investment Advisory Services LLC grew its holdings in shares of Amgen by 2.3% during the fourth quarter. CFS Investment Advisory Services LLC now owns 9,235 shares of the medical research company’s stock worth $3,023,000 after purchasing an additional 206 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Morgan Stanley set a $332.00 target price on Amgen in a report on Friday, May 1st. Erste Group Bank reissued a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Wells Fargo & Company boosted their target price on Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a report on Thursday, March 19th. Citigroup boosted their target price on Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Finally, Guggenheim reduced their target price on Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a report on Monday, May 4th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Amgen has an average rating of “Hold” and a consensus target price of $355.19.

Amgen Price Performance

Shares of AMGN opened at $336.79 on Friday. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29. The company has a market capitalization of $181.77 billion, a price-to-earnings ratio of 23.44, a price-to-earnings-growth ratio of 3.38 and a beta of 0.44. The firm has a 50-day simple moving average of $342.53 and a 200-day simple moving average of $345.33. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the prior year, the firm earned $4.90 earnings per share. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 22.37 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. Amgen’s dividend payout ratio is 70.15%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.